Bone Void Fillers
A Technology Overview

Adopted by the American Academy of Orthopaedic Surgeons
Board of Directors
March 8, 2010

This Technology Overview was prepared by an AAOS physician task force using systematic review methodology, and summarizes the findings of studies published as of October 8, 2009 on bone void fillers. As a summary, this document does not make recommendations for or against the use of bone void fillers. It should not be construed as an official position of the American Academy of Orthopaedic Surgeons. Readers are encouraged to consider the information presented in this document and reach their own conclusions concerning the use of synthetic bone void fillers.

The American Academy of Orthopaedic Surgeons has developed and is providing this Technology Overview as an educational tool. Patient care and treatment should always be based on a clinician’s independent medical judgment given the individual patient’s clinical circumstances.
**Disclaimer**
This technology overview was developed by an AAOS physician volunteer task force based on a systematic review of the current scientific and clinical information and accepted approaches to treatment and/or diagnosis. This technology overview is not intended to be a fixed protocol, as some patients may require more or less treatment or different means of diagnosis. Clinical patients may not necessarily be the same as those found in a clinical trial. Patient care and treatment should always be based on a clinician’s independent medical judgment, given the individual patient’s clinical circumstances.

**Disclosure Requirement**
In accordance with AAOS policy, all individuals whose names appear as authors or contributors to this technology overview filed a disclosure statement as part of the submission process. All panel members provided full disclosure of potential conflicts of interest prior to developing the key questions contained within this technology overview.

**Funding Source**
This technology overview was funded exclusively by the American Academy of Orthopaedic Surgeons who received no funding from outside commercial sources to support the development of this document.

**FDA Clearance**
Some drugs or medical devices referenced or described in this technology overview may not have been cleared by the Food and Drug Administration (FDA) or may have been cleared for a specific use only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.

**Copyright**
All rights reserved. No part of this technology overview may be reproduced, stored in a retrieval system, or transmitted, in any form, or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the AAOS.

Published 2010 by the American Academy of Orthopaedic Surgeons
6300 North River Road
Rosemont, IL 60018
First Edition
Copyright 2010 by the American Academy of Orthopaedic Surgeons
SUMMARY OF PUBLISHED RESULTS
The available literature on synthetic bone void fillers is not expansive enough to be conclusive. Bearing this in mind, summaries of the data that pertain to the five key questions addressed in this Technology Overview are summarized below:

KEY QUESTION 1
Do patients treated with synthetic bone void fillers (alone) as a graft material have different clinical results when compared to patients treated with iliac crest bone grafts (autografts but not local autograft) in a posterolateral spine fusion?

To answer this question we included one Level II study (n= 40 patients) and one Level IV study (n= 90 patients) that compared synthetic bone void fillers to autogenous iliac crest grafts. The Level II study addressed adolescent patients with idiopathic scoliosis. The level IV study addressed adult patients diagnosed with degenerative spondylolisthesis, isthmic spondylolistesis, disk herniation with instability, or canal stenosis. In addition, the studies reported different surgical instrumentation. Outcomes for these studies are summarized by patient population.

Of the five outcomes reported for adolescents, there was a statistically significant difference favoring synthetic bone void filler in overall VAS pain at hospital discharge but not at longer term follow-up. Donor site pain, a common complaint in patients treated with autogenous iliac crest grafting, was also reported at hospital discharge and 48 months postoperatively; the difference in overall VAS pain scores was statistically significantly improved at 48 months. Adolescents had more intraoperative complications in the iliac crest bone graft group.

The adult population in the Level IV study was reported to have operating times and blood loss that was statistically significant in favor of synthetic bone void filler. This study also reported that “the roentgenographic analysis appeared insufficient to determine the quality of fusion”.

KEY QUESTION 2
Do patients treated with synthetic bone void fillers that are supplemented with autograft have different clinical results than patients treated with local autografts alone in a posterolateral spine fusion?

Our literature searches did not identify any peer reviewed data that addressed this question.
KEY QUESTION 3
Do patients with metaphyseal defects as a result of fractures have different clinical outcomes if they are treated with synthetic bone void filler, allograft, or autograft in the defect?

We included three Level II studies (n=161 patients) that compared synthetic bone void filler to autogenous bone in patients with metaphyseal defects as a result of fractures. There was no statistically significant difference between groups in any of the eight outcome measures. Two studies reported donor site pain, a common complain of patients undergoing autogenous iliac crest grafting. Dickson, et al. reported that no patients experienced donor site pain 6 and 12 months after surgery. Russell, et al. reported that all patients had donor site pain at hospital discharge. Of the eighteen complications reported, there was a statistically significant difference between groups in two complications (implant site infection and stitch abscess) both in favor of the autograft group.

Our literature searches did not identify any data that compare synthetic bone void fillers to allografts.

KEY QUESTION 4
Do patients with contained defects from tumor (or other benign bone cysts) have different clinical outcomes when treated with synthetic bone void filler, autograft, or allograft?

Our literature searches did not identify any peer reviewed data that addressed this question.

KEY QUESTION 5
Do patients with contained defects from peri-prosthetic bone loss have different clinical outcomes when treated with synthetic bone void filler, allograft, or autograft?

Our literature searches did not identify any peer reviewed data that addressed this question.
# Table of Contents

## BONE VOID FILLERS

### A TECHNOLOGY OVERVIEW

Summary of Published Results

Key Question 1
Key Question 2
Key Question 3
Key Question 4
Key Question 5

---

## TABLE OF CONTENTS

### I. INTRODUCTION

---

### II. METHODS

Methods Overview
Included Articles
Quality of the Literature
Outcomes Considered
Minimal Clinically Important Improvement

### III. KEY QUESTIONS AND SUPPORTING EVIDENCE

Key Question 1
Key Question 2
Key Question 3
Key Question 4
Key Question 5

---

### IV. APPENDIXES

Appendix I
Appendix II

---

5
Appendix III
Study Attrition

Appendix IV
Study Quality Checklists

Appendix V
Documentation of Approval
AAOS Bodies that Approved this Technology Overview

Appendix VI
Task Force
Conflict of Interest

Appendix VII
Excluded Studies
I. INTRODUCTION

Synthetic bone void fillers (SBVF) are available for a variety of indications in orthopaedic surgery. The number of available products and information complicates surgical decisions regarding bone graft substitutes. Graft substitutes may be grouped as synthetic (predominantly osteo-conductive) or biological (predominantly osteo-inductive). The scope of this Technology Overview is to evaluate the synthetic or predominantly osteo-conductive graft materials. The task force that prepared the present report posed question 1 to address the use of synthetic bone void fillers alone. We posed question 2 to determine if synthetic bone void fillers could work as graft extenders and thus eliminate the need for Iliac Crest Bone Graft. Questions 3, 4 and 5 included the use of allografts as a comparison because clinical results with allografts are perceived as much closer to autografts in these areas of the spine. The task force limited the scope to materials that had some degree of structural integrity to support loading in the indications of fracture, tumor reconstruction and periprosthetic reconstruction and as such, this overview does not include demineralized products.

Volunteers were sought to assemble a task force to frame questions and provide guidance for this Technology Overview. These volunteers were experienced in the use of synthetic bone void fillers in subspecialty areas of spine, trauma, oncology, and adult reconstruction. This technology overview was done in an attempt to inform the membership of the current knowledge of clinical results using synthetic bone void filers for common clinical problems.
II. METHODS

METHODS OVERVIEW
This report was developed using the methods of a systematic review. We began by having a panel of physicians frame five key questions, and next developed rules (inclusion criteria) for determining what information we would include (The full list of criteria appears in Appendix I). Finally, we conducted comprehensive literature searches (Appendix II) to ensure that the data we considered are not biased in favor of any particular point of view. Thereafter, we evaluated the quality of the relevant studies, including their methods of analysis, considered their results, and summarized this information in graphs and tables.

INCLUDED ARTICLES
Our searches identified 1508 citations. Of these, five met the inclusion criteria and were used to address two of the five key questions. This information forms the dataset that we used to address the key questions.

We emphasize that this is a Technology Overview of synthetic bone void fillers alone. Therefore, our dataset does not include studies that combined bone void fillers with bone morphogenic proteins or demineralized bone matrices.

QUALITY OF THE LITERATURE
Assessing the quality of evidence is an important step in a systematic review. Readers can have more confidence in the results of high quality studies than low quality studies. To assess quality, we used a Levels of Evidence System. Many such systems examine only study design. Design alone, however, does not adequately reflect the quality of a study. Therefore, we assessed study quality using a system that considers not only design, but also several aspects of how well a study was conducted. Details about this system are provided in Appendix I. We evaluated quality on a per outcome basis rather than a per study basis because quality is not necessarily the same for all outcomes and all follow-up times reported in a study.

We assessed the quality of treatment studies using a two step process. First, we assigned a level of evidence to all results reported in a study based solely on that study’s design. Accordingly, all data presented in randomized controlled trials were initially categorized as Level I evidence, all results presented in non-randomized controlled trials and other prospective comparative studies were initially categorized as Level II. We next assessed each outcome at each reported time point using a quality questionnaire and, when quality standards were not met, downgraded the level of evidence (for this outcome at this time point) by one level.

OUTCOMES CONSIDERED
This overview only includes patient-oriented outcomes. This is because patient-oriented outcomes are outcomes that matter to patients and indicate, without the need for extrapolation, whether an intervention is effective.1 Patient-oriented outcomes include
outcomes like pain, quality of life, ability to perform activities of daily living, and revision surgery. Unlike use of patient-oriented outcomes, use of surrogate outcomes such as imaging results or laboratory test results can be misleading, and can even make harmful treatments look beneficial.²

Because donor site pain is a common complaint among patients treated with an autogenous iliac crest graft, we have reported donor site pain where available. We have also reported any other complications that were reported by the authors.

**MINIMAL CLINICALLY IMPORTANT IMPROVEMENT**

Wherever possible, we considered the effects of treatments in terms of the minimal clinically important improvement (MCII) in addition to whether their effects were statistically significant. The MCII is the smallest clinical change that is important to patients, and recognizes the fact that there are some treatment-induced statistically significant improvements that are too small to matter to patients. The values we used for MCIIs are derived from a published study investigating the Visual Analogue Scale, the Numerical Rating Scale, the Oswestry Disability Index, and the Roland Disability Questionnaire.³

**Table 1 MCII of outcomes**

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>MCII (points)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain – VAS (0-100)</td>
<td>15</td>
</tr>
</tbody>
</table>

The associated descriptive terms in this guideline and the conditions for using each of these terms, are outlined in the following table:

**Table 2 Descriptive terms for results with MCII**

<table>
<thead>
<tr>
<th>Descriptive Term</th>
<th>Condition for Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinically Important</td>
<td>Statistically significant and lower confidence limit &gt; MCII</td>
</tr>
<tr>
<td>Possibly Clinically Important</td>
<td>Statistically significant and confidence intervals contain the MCII</td>
</tr>
<tr>
<td>Not Clinically Important</td>
<td>Statistically significant and upper confidence limit &lt; MCII</td>
</tr>
<tr>
<td>Negative</td>
<td>Not statistically significant and upper confidence limit &lt; MCII</td>
</tr>
<tr>
<td>Inconclusive</td>
<td>Not statistically significant but confidence intervals contain the MCII</td>
</tr>
</tbody>
</table>
To determine if a study was sufficiently powered to detect the MCII, we consulted Cohen, J., “Statistical Power Analysis for the Behavioral Sciences”, 1st Edition, Lawrence Erlbaum Associates, Hillsdale (2nd Edition, 1988). For these calculations, we assumed that the statistical test was a 2-tailed paired t-test on pre- and post-treatment results and determined whether the number of patients in the study was sufficient to detect a significant difference while assuming an alpha of 0.05 as the significance level and 80% power. All outcomes that are not statistically significant with the exception of two (malunion in Russel et al. and delayed deep wound infection in Fujibayashi, et al.) are underpowered.
III. KEY QUESTIONS AND SUPPORTING EVIDENCE

KEY QUESTION 1
Do patients treated with synthetic bone void fillers (alone) as a graft material have different clinical results when compared to patients treated with iliac crest bone grafts (autografts but not local autograft) in a posterolateral spine fusion?

To answer this question we included one Level II study and one Level IV study that compared synthetic bone void fillers to autogenous iliac crest grafts (please see Table 9 for further information about the quality of these studies). The Level II study addressed adolescent patients with idiopathic scoliosis. The level IV study addressed adult patients diagnosed with degenerative spondylolisthesis, isthmic spondylolisthesis, disk herniation with instability, or canal stenosis (Table 3). In addition, the studies report different surgical instrumentation. Outcomes for these studies are summarized by patient population. Please see Table 4, Table 5, Table 6, and Table 10 for the results of these studies.

Of the five outcomes reported for adolescents, there was a statistically significant but not clinically important difference favoring synthetic bone void filler in overall VAS pain at hospital discharge but not at longer term follow-up (Table 4). Donor site pain, a common complaint in patients treated with autogenous iliac crest grafting, was also reported at hospital discharge and 48 months postoperatively; the difference in overall VAS pain scores was statistically significantly improved but not clinically important at 48 months (see Table 5). Adolescents had more intraoperative complications in the iliac crest bone graft group (Table 6).

The adult population in the Level IV study was reported to have operating times and blood loss that was statistically significant in favor of synthetic bone void filler (Table 4). There was also a 10.3 point difference on the JOA scale in adults at 33.5 months in favor of the synthetic bone void filler group; however, there was not enough data available in the study to determine whether this difference was statistically significant (Table 5). This study also reported that “the roentgenographic analysis appeared insufficient to determine the quality of fusion”. The raw data extracted from each study can be found in Table 10.
<table>
<thead>
<tr>
<th>Author</th>
<th>LOE</th>
<th>N</th>
<th>Age</th>
<th>Comparison (Type of Bone Void Filler)</th>
<th>Instrumentation</th>
<th>Surgery</th>
<th>Indication for Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>18.5 yrs</td>
<td>ultra porous β-tricalcium phosphate versus autograft from the posterior iliac crest</td>
<td>Posterior corrective using titanium pedicle screw and rod system and fusion with additional grafting</td>
<td>Posterior Correction and Fusion</td>
<td>Adolescent Idiopathic Scoliosis</td>
</tr>
<tr>
<td>Fujibayashi, et al. 2001</td>
<td>IV</td>
<td>90</td>
<td>55.3 yrs</td>
<td>HAP-TCO, a biphasic calcium phosphate ceramic containing hydroxyapatite and beta-tricalcium phosphate in microporous form versus autogenous iliac crest</td>
<td>Transpediculare instrumentation</td>
<td>Single level posterolateral spinal fusion (16 cases with isthmic spondylolisthesis and severe instability required a combination of posterior underbody fusion with designed HAP-TCP)</td>
<td>Degenerative spondylolisthesis, isthmic spondylolistesis, Disk herniation with instability, Canal stenosis</td>
</tr>
</tbody>
</table>
Table 4. Bone Void Filler vs. Autogenous Iliac Crest – Summary Results

<table>
<thead>
<tr>
<th>Author</th>
<th>LOE</th>
<th>N</th>
<th>Outcome</th>
<th>Duration</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Difference between groups in overall VAS</td>
<td>Hospital Discharge</td>
<td>●‡ BVF</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Difference between groups in overall VAS</td>
<td>48 months</td>
<td>○</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Difference between groups in VAS back</td>
<td>Hospital Discharge</td>
<td>○</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Difference between groups in VAS back</td>
<td>48 months</td>
<td>○</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Use of analgesics</td>
<td>Hospital Discharge</td>
<td>○*</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Use of analgesics</td>
<td>48 months</td>
<td>○*</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Operating Time</td>
<td>Intraoperative</td>
<td>○</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Blood Loss</td>
<td>Intraoperative</td>
<td>○</td>
</tr>
<tr>
<td>Fujibayashi, et al 2001</td>
<td>IV</td>
<td>90</td>
<td>Operating Time</td>
<td>Intraoperative</td>
<td>● BVF</td>
</tr>
<tr>
<td>Fujibayashi, et al 2001</td>
<td>IV</td>
<td>90</td>
<td>Blood Loss</td>
<td>Intraoperative</td>
<td>● BVF</td>
</tr>
<tr>
<td>Fujibayashi, et al 2001</td>
<td>IV</td>
<td>90</td>
<td>JOA</td>
<td>33.9 months (range 26-50 months)</td>
<td>mean change 10.3 points**</td>
</tr>
</tbody>
</table>

*= AAOS calculated using arcsin transform
●BVF= statistically significant in favor of Bone Void Filler group
○= No statistically significant difference between groups
**= There was not enough data provided to determine whether results are statistically significant.
●‡= Statistically significant but not clinically important
Table 5. Donor site pain measured on the VAS in the Autograft group

<table>
<thead>
<tr>
<th>Author</th>
<th>LoE</th>
<th>N</th>
<th>Outcome</th>
<th>Duration</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lerner, et al.</td>
<td>II</td>
<td>40</td>
<td>VAS Pain Iliac Crest- Change from hospital discharge to 48 months</td>
<td>48 months</td>
<td>$p=0.003^*$ BVF</td>
</tr>
</tbody>
</table>

*AAOS calculated using t-test

BVF= Statistically significant in favor of Bone Void Filler Group but not clinically important

Table 6. Bone Void Filler vs. Autogenous Iliac Crest - Results Complications

<table>
<thead>
<tr>
<th>Author</th>
<th>LoE</th>
<th>N</th>
<th>Complication</th>
<th>Duration</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lerner, et al.</td>
<td>II</td>
<td>40</td>
<td>Intraoperative Complications: Prolonged wake-up test (&gt;30 minutes) including one patient with extensive bleeding diathesis and blood loss</td>
<td>In hospital</td>
<td>$p=0.001^*$ Autograft</td>
</tr>
<tr>
<td>Lerner, et al.</td>
<td>II</td>
<td>40</td>
<td>Pleural Effusion without the need for pleuracentesis</td>
<td>48 months</td>
<td>$p=.63^*$</td>
</tr>
<tr>
<td>Lerner, et al.</td>
<td>II</td>
<td>40</td>
<td>Subcutaneous seroma requiring puncture</td>
<td>48 months</td>
<td>$p=1^*$</td>
</tr>
<tr>
<td>Lerner, et al.</td>
<td>II</td>
<td>40</td>
<td>Revision of one screw which was placed in close proximity to the aorta</td>
<td>48 months</td>
<td>$p=0.15^*$</td>
</tr>
<tr>
<td>Lerner, et al.</td>
<td>II</td>
<td>40</td>
<td>Pseudarthrosis which was revised</td>
<td>48 months</td>
<td>$p=0.15^*$</td>
</tr>
<tr>
<td>Fujibayashi, et al.</td>
<td>III</td>
<td>90</td>
<td>Delayed deep wound infection resulting in removal of the instrument and graft bone</td>
<td>1 year</td>
<td>$p=0.23^*$</td>
</tr>
</tbody>
</table>

* AAOS Calculated using arcsin transform

Autograft= Statistically Significant in favor of Autograft group

** Per this study⁵, page 216, “Roentgenographic analysis appeared insufficient to determine the quality of fusion.”
### STUDIES CONSIDERED

#### Table 7. Included Studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fujibayashi, et al. 2001</td>
<td>Lumbar posterolateral fusion with biphasic calcium phosphate ceramic</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>A level-1 pilot study to evaluate of ultra porous beta-tricalcium phosphate as a graft extender in the posterior correction of adolescent idiopathic scoliosis</td>
</tr>
</tbody>
</table>

#### Table 8. Excluded Studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>Reason for Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>McConnell, et al. 2003</td>
<td>A prospective randomized comparison of coralline hydroxyapatite with autograft in cervical interbody fusion</td>
<td>Less than 80% underwent posterlateral fusion</td>
</tr>
<tr>
<td>Neen, et al. 2006</td>
<td>Healos and bone marrow aspirate used for lumbar spine fusion: a case controlled study comparing healos with autograft</td>
<td>Cervical Interbody Fusion</td>
</tr>
</tbody>
</table>
## STUDY QUALITY

### Table 9. Study Quality

<table>
<thead>
<tr>
<th>Author</th>
<th>Outcome</th>
<th>Duration</th>
<th>Level of Evidence</th>
<th>RCT-Stochastic randomization</th>
<th>RCT- Allocation concealment</th>
<th>RCT- Patients blinded</th>
<th>RCT-Assessor blinded</th>
<th>RCT-80% Follow-up</th>
<th>RCT-Equal outcomes at entry</th>
<th>Retro Comparative- Less than 20% completion rate difference</th>
<th>Retro Comparative- Groups treated concurrently</th>
<th>Retro Comparative- Same Treatment in both groups</th>
<th>Retro Comparative- Same outcomes measured in both groups</th>
<th>Retro Comparative- Follow-up 80% in both groups</th>
<th>Retro Comparative- Patients treated at the same center</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lerner, et al. 2009</td>
<td>Difference between groups in VAS back</td>
<td>48 months</td>
<td>II</td>
<td>NR</td>
<td>Y</td>
<td>NR</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>Use of analgesics Hospital Discharge</td>
<td></td>
<td>II</td>
<td>NR</td>
<td>Y</td>
<td>NR</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>Use of analgesics 48 months</td>
<td></td>
<td>II</td>
<td>NR</td>
<td>Y</td>
<td>NR</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>Operating Time Intraoperative</td>
<td></td>
<td>II</td>
<td>NR</td>
<td>Y</td>
<td>NR</td>
<td>Y</td>
<td>Y</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Fujibayashi S, et al. 2001</td>
<td>Operating Time Intraoperative</td>
<td></td>
<td>IV</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Fujibayashi S, et al. 2001</td>
<td>Blood Loss Intraoperative</td>
<td></td>
<td>IV</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Author</td>
<td>Outcome</td>
<td>Duration</td>
<td>Level of Evidence</td>
<td>RCT-Stochastic randomization</td>
<td>RCT- Allocation concealment</td>
<td>RCT- Patients blinded</td>
<td>RCT-Assessor blinded</td>
<td>RCT-80% Follow-up</td>
<td>RCT-Equal outcomes at entry</td>
<td>Retro Comparative- Less than 20% completion rate difference</td>
<td>Retro Comparative- Groups treated concurrently</td>
<td>Retro Comparative- Same Treatment in both groups</td>
<td>Retro Comparative- Same outcomes measured in both groups</td>
<td>Retro Comparative- Follow-up 80% in both groups</td>
<td>Retro Comparative- Patients treated at the same center</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------</td>
<td>----------------</td>
<td>-------------------</td>
<td>-----------------------------</td>
<td>----------------------------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>-----------------------------</td>
<td>-------------------------------------------------------------</td>
<td>------------------------------------------------</td>
<td>-------------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>Fujibayashi S, et al. 2001</td>
<td>JOA</td>
<td>33.9 months</td>
<td>IV</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
</tbody>
</table>

Y= Yes

N= No

NR= Not reported in study

NA= Not applicable to specific study
### STUDY DATA

#### Table 10. Study Data

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>LOE</th>
<th>N</th>
<th>Outcome Description</th>
<th>Duration</th>
<th>Group Result</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Difference between groups in overall VAS</td>
<td>Hospital Discharge</td>
<td>2.9 ± 3</td>
<td>3.9±4</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Difference between groups in overall VAS</td>
<td>48 months</td>
<td>1.9 ± 1</td>
<td>2.3 ± 2</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Difference between groups in VAS back</td>
<td>Hospital Discharge</td>
<td>2.9 ± 3</td>
<td>3.5 ± 4</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Difference between groups in VAS back</td>
<td>48 months</td>
<td>1.9 ± 1</td>
<td>1.9 ± 1</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Use of analgesics</td>
<td>Hospital Discharge</td>
<td>9</td>
<td>12</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Use of analgesics</td>
<td>48 months</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Operating Time</td>
<td>Intraoperative</td>
<td>212.3 ± 205</td>
<td>222.5 ± 227</td>
</tr>
<tr>
<td>Fujibayashi, et al 2001</td>
<td>II</td>
<td>90</td>
<td>Operating Time</td>
<td>Intraoperative</td>
<td>143±31.4</td>
<td>158±29.7</td>
</tr>
<tr>
<td>Lerner, et al. 2009</td>
<td>II</td>
<td>40</td>
<td>Blood Loss</td>
<td>Intraoperative</td>
<td>1124</td>
<td>1020</td>
</tr>
<tr>
<td>Fujibayashi, et al 2001</td>
<td>II</td>
<td>90</td>
<td>Blood Loss</td>
<td>Intraoperative</td>
<td>291.2±191.6</td>
<td>416.4±309.3</td>
</tr>
<tr>
<td>Fujibayashi, et al 2001</td>
<td>II</td>
<td>90</td>
<td>JOA</td>
<td>33.9 months (range 26-50 months)</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

AICG= Autogenous Iliac Crest Graft  
BVF= Statistically significant in favor of Synthetic Bone Void Filler  
*= AAOS calculated using the arcsine transform
KEY QUESTION 2
Do patients treated with synthetic bone void fillers that are supplemented with autograft have different clinical results than patients treated with local autografts alone in a posterolateral spine fusion?

Our literature searches did not identify any peer reviewed data that addresses this question.

This question specifically addresses the comparison of synthetic bone void fillers supplemented with autograft to local autograft alone. No studies that examined this specific comparison were identified.

Table 11 Excluded Studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>Reason for Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moro-Barrero, et al. 2007</td>
<td>Radiographic analysis of fusion mass using fresh autologous bone marrow with ceramic composites as an alternative to autologous bone graft</td>
<td>Both treatment group and study group are in the same patients- Confounded study design</td>
</tr>
<tr>
<td>Chang, et al. 2008</td>
<td>Local autogenous bone mixed with bone expander: an optimal option of bone graft in single-segment posterolateral lumbar fusion</td>
<td>Autograft plus BVF vs. iliac crest</td>
</tr>
<tr>
<td>Chen, et al. 2005</td>
<td>The fusion rate of calcium sulfate with local autograft bone compared with autologous iliac bone graft for instrumented short-segment spinal fusion</td>
<td>BVF plus local autograft vs. iliac crest</td>
</tr>
<tr>
<td>Dai, et al. 2008</td>
<td>Single-level instrumented posterolateral fusion of lumbar spine with beta-tricalcium phosphate versus autograft: a prospective, randomized study with 3-year follow-up</td>
<td>BVF plus Local Bone vs. Iliac Crest</td>
</tr>
<tr>
<td>Gunzburg, et al. 2002</td>
<td>Use of a novel beta-tricalcium phosphate-based bone void filler as a graft extender in spinal fusion surgeries</td>
<td>Does not answer the question: non-comparative data</td>
</tr>
<tr>
<td>Hsu, et al. 2005</td>
<td>Coralline hydroxyapatite and laminectomy-derived bone as adjuvant graft material for lumbar posterolateral fusion</td>
<td>Iliac Crest vs. three different combinations</td>
</tr>
<tr>
<td>Gitelis, et al. 2001</td>
<td>Use of a calcium sulfate-based bone graft substitute for benign bone lesions</td>
<td>Not local autograft</td>
</tr>
<tr>
<td>Bose, et al. 2003</td>
<td>Results of a Calcium Sulfate Bone Graft Substitute Used to Promote Posterolateral Lumbar Spinal Fusion</td>
<td>Not local autograft</td>
</tr>
</tbody>
</table>
KEY QUESTION 3
Do patients with metaphyseal defects as a result of fractures have different clinical outcomes if they are treated with synthetic bone void filler, allograft, or autograft in the defect?

Three Level II studies\(^4,7,8\) compared synthetic bone void filler to autograft in patients with metaphyseal defects (periarticular, metaphyseal bone loss) as a result of fracture. Information about the study populations and the surgery details can be found in Table 12. Please see Table 18 for quality information and Table 12 through Table 15 and Table 19 for results reported in each of these studies.

Of the eight outcome measures reported, there was no statistically significant difference between synthetic bone void fillers and autografts (Table 13). Twelve month outcomes reported by Dickson, et al.\(^1\) were not included in this Overview because patient loss to follow up resulted in one group with fewer than 10 patients. Patient enrollment greater than ten is an \textit{a priori} inclusion criteria. Detailed information regarding inclusion criteria can be found in Appendix I.

Donor site pain was recorded at hospital discharge in one study and at 6 and twelve months in another. 100% of patients had donor site pain at discharge, however, at both 6 and twelve months after surgery, 0% of patients enrolled in the Dickson, et al.\(^7\) study reported pain at the donor site (Table 14).

Of 18 reported complications, 2 were statistically different in favor of the autograft group, stitch abscess and implant site infection (Table 15).

We did not identify any studies that compare synthetic bone void filler to allograft in this patient population.
<table>
<thead>
<tr>
<th>Author</th>
<th>LOE</th>
<th>N</th>
<th>Age (mean)</th>
<th>Comparison</th>
<th>Fixation</th>
<th>Indication for Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dickson, et al.</td>
<td>II</td>
<td>29</td>
<td>42.43</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>Internal or External*</td>
<td>Type I fracture of the humerus, radius, ulna, femur, tibia, or calcaneus who had a traumatic bone void</td>
</tr>
<tr>
<td>Bucholz, et al.</td>
<td>II</td>
<td>40</td>
<td>36.7-37.5</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>Internal Fixation</td>
<td>Closed tibial fbrate fractures associated metaphyseal defects</td>
</tr>
<tr>
<td>Russell, et al.</td>
<td>II</td>
<td>92</td>
<td>43</td>
<td>Alpha BSM versus autogenous iliac bone graft</td>
<td>Internal Fixation</td>
<td>Acute, closed, unstable fracture of the proximal part of the tibia</td>
</tr>
</tbody>
</table>

* Fixation based on physician preference
<table>
<thead>
<tr>
<th>Author</th>
<th>LoE</th>
<th>N</th>
<th>Comparison</th>
<th>Duration</th>
<th>Outcome</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Fracture Healing- completely healed</td>
<td>○</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Fracture Healing- Partial Healed</td>
<td>○</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Fracture Healing Nonunion</td>
<td>○</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Pain at the defect site- None</td>
<td>○</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Pain at the defect site- severe</td>
<td>○</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Function of the fractured limb- maximum</td>
<td>○</td>
</tr>
<tr>
<td>Author</td>
<td>LoE</td>
<td>N</td>
<td>Comparison</td>
<td>Duration</td>
<td>Outcome</td>
<td>Results</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----</td>
<td>-----</td>
<td>-----------------------------------------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Overall Success</td>
<td>○</td>
</tr>
<tr>
<td>Bucholz, et al. 1989</td>
<td>IV</td>
<td>40</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>15.4-34.5 months</td>
<td>Knee pain</td>
<td>○</td>
</tr>
<tr>
<td>Bucholz, et al. 1989</td>
<td>IV</td>
<td>40</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>15.4-34.5 months</td>
<td>Return to pre-injury employment</td>
<td>○</td>
</tr>
</tbody>
</table>

* = AAOS Calculated arcsine transform
○ = No statistically significant difference
Table 14. Percent of patients reporting Iliac Crest Donor Site Pain

<table>
<thead>
<tr>
<th>Author</th>
<th>LoE</th>
<th>N</th>
<th>Outcome</th>
<th>Duration</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>15</td>
<td>Donor site Pain</td>
<td>6 months</td>
<td>0%</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>12</td>
<td>Donor site Pain</td>
<td>12 months</td>
<td>0%</td>
</tr>
<tr>
<td>Russell, et al. 2008</td>
<td>II</td>
<td>38</td>
<td>Donor site Pain</td>
<td>Immediately following surgery</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 15 Bone void filler vs. autograft - Complications

<table>
<thead>
<tr>
<th>Author</th>
<th>LoE</th>
<th>N</th>
<th>Comparison</th>
<th>Complication</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>Ankylosis</td>
<td>$p= 0.13^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>Stitch Abscess</td>
<td>$p= 0.03^* AIC$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>Implant site infection</td>
<td>$p=0.03^* AIC$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>wound drainage</td>
<td>$p= 0.88^*$</td>
</tr>
<tr>
<td>Author</td>
<td>LoE</td>
<td>N</td>
<td>Comparison</td>
<td>Complication</td>
<td>Results</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----</td>
<td>---</td>
<td>-------------------------------------------------</td>
<td>----------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>carpal tunnel</td>
<td>$p = 0.13^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>surgical site infection</td>
<td>$p = 0.13^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>Skin necrosis</td>
<td>$p = 0.18^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>granulation</td>
<td>$p = 0.18^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>pin-track infection</td>
<td>$p = 0.18^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>graft site infection</td>
<td>$p = 0.18^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>fracture blister</td>
<td>$p = 0.18^*$</td>
</tr>
<tr>
<td>Author</td>
<td>LoE</td>
<td>N</td>
<td>Comparison</td>
<td>Complication</td>
<td>Results</td>
</tr>
<tr>
<td>---------------------</td>
<td>-----</td>
<td>-----</td>
<td>-----------------------------------------------------</td>
<td>-----------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>30</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>pain at graft site harvest</td>
<td>$p=0.18^*$</td>
</tr>
<tr>
<td>Russell, et al</td>
<td>II</td>
<td>92</td>
<td>alpha BSM versus autogenous iliac bone graft</td>
<td>Malunion</td>
<td>$p=0.50^*$</td>
</tr>
<tr>
<td>Bucholz, et al 1989</td>
<td>II</td>
<td>40</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>loss of reduction</td>
<td>$p=0.28^*$</td>
</tr>
<tr>
<td>Bucholz, et al 1989</td>
<td>II</td>
<td>40</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>painful, prominent plates</td>
<td>$p=1.00^*$</td>
</tr>
<tr>
<td>Bucholz, et al 1989</td>
<td>II</td>
<td>40</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>loose screws</td>
<td>$p=0.28^*$</td>
</tr>
<tr>
<td>Bucholz, et al 1989</td>
<td>II</td>
<td>40</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>deep wound infection</td>
<td>$p=0.54^*$</td>
</tr>
<tr>
<td>Bucholz, et al 1989</td>
<td>II</td>
<td>40</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>contiguous septic knee</td>
<td>$p=0.15^*$</td>
</tr>
</tbody>
</table>

* = AAOS Calculated arcsine transform

AIC = In favor of Autogenous Iliac Crest Group
### STUDIES CONSIDERED

#### Table 16. Included Studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dickson, et al. 2002</td>
<td>The use of hydroxyapatite cement for traumatic metaphyseal bone void filling</td>
</tr>
<tr>
<td>Bucholz, et al. 1989</td>
<td>Interporous hydroxyapatite as a bone graft substitute in tibial plateau fractures</td>
</tr>
</tbody>
</table>

#### Table 17. Excluded Studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>Reason for Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornell, et al. 1991</td>
<td>Multicenter trial of Collagraft as bone graft substitute</td>
<td>C-porous calcium phosphate ceramic plus autogenous bone marrow aspirated from the iliac crest(Collagen) vs. Autogenous cancellous graft from iliac crest</td>
</tr>
<tr>
<td>Cornell, et al. 1992</td>
<td>Initial clinical experience with use of Collagraft(TM) as a bone graft substitute</td>
<td>C-porous calcium phosphate ceramic plus autogenous bone marrow aspirated from the iliac crest(Collagen) vs. Autogenous cancellous graft from iliac crest</td>
</tr>
</tbody>
</table>
### STUDY QUALITY

**Table 18. Study quality**

<table>
<thead>
<tr>
<th>Author</th>
<th>Outcome Measure</th>
<th>Duration</th>
<th>Level of Evidence</th>
<th>RCT-Stochastic randomization</th>
<th>RCT- Allocation concealment</th>
<th>RCT- Patients blinded</th>
<th>RCT- Assessor blinded</th>
<th>RCT-80% Follow-up</th>
<th>RCT-Equal outcomes at entry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dickson, et al. 2001</td>
<td>Fracture Healing- completely healed</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Fracture Healing- completely healed</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Fracture Healing- Partially Healed</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Fracture Healing Nonunion</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Pain at the defect site- None</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Pain at the defect site</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Author</td>
<td>Outcome Measure</td>
<td>Duration</td>
<td>Level of Evidence</td>
<td>RCT-Stochastic randomization</td>
<td>RCT-Allocation concealment</td>
<td>RCT-Patients blinded</td>
<td>RCT-Assessor blinded</td>
<td>RCT-80% Follow-up</td>
<td>RCT-Equal outcomes at entry</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------</td>
<td>----------</td>
<td>-------------------</td>
<td>-----------------------------</td>
<td>----------------------------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Pain at the defect site-severe</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Function of the fractured limb-maximum/moderate</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Function of the fractured limb-maximum</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Function of the fractured limb-minimal/none</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Overall Success</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Donor Site Pain</td>
<td>6 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>Donor Site Pain</td>
<td>12 months</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Author</td>
<td>Outcome Measure</td>
<td>Duration</td>
<td>Level of Evidence</td>
<td>RCT-Stochastic randomization</td>
<td>RCT- Allocation concealment</td>
<td>RCT- Patients blinded</td>
<td>RCT- Assessor blinded</td>
<td>RCT- 80% Follow-up</td>
<td>RCT- Equal outcomes at entry</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>------------------------------</td>
<td>-----------------------------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Russell, et al. 2007</td>
<td>Donor Site Pain</td>
<td>Immediate</td>
<td>II</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
</tr>
<tr>
<td>Bucholz et al. 1989</td>
<td>Knee pain</td>
<td>15.4- 34.5 months</td>
<td>II</td>
<td>N</td>
<td>NR</td>
<td>NR</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Bucholz et al. 1989</td>
<td>Return to pre-injury employment</td>
<td>15.4- 34.5 months</td>
<td>II</td>
<td>N</td>
<td>NR</td>
<td>NR</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
</tbody>
</table>

Y = Yes  
NR = Not reported in study  
N = No
<table>
<thead>
<tr>
<th>Author</th>
<th>LoE</th>
<th>N</th>
<th>Comparison</th>
<th>Duration</th>
<th>Outcome</th>
<th>Group Result</th>
<th>BVF</th>
<th>Autograft</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Fracture Healing- completely healed</td>
<td>11</td>
<td>15</td>
<td></td>
<td>$p=0.42^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Fracture Healing- Partially Healed</td>
<td>1</td>
<td>0</td>
<td></td>
<td>$p=0.13^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Fracture Healing- Nonunion</td>
<td>0</td>
<td>0</td>
<td></td>
<td>$p=1.0^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Pain at the defect site- None</td>
<td>10</td>
<td>9</td>
<td></td>
<td>$p=0.23^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Pain at the defect site</td>
<td>3</td>
<td>7</td>
<td></td>
<td>$p=0.23^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Function of the fractured limb- maximum/moderate</td>
<td>11</td>
<td>15</td>
<td></td>
<td>$p=0.42^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Function of the fractured limb- minimal/none</td>
<td>2</td>
<td>1</td>
<td></td>
<td>$p=0.42^*$</td>
</tr>
<tr>
<td>Dickson, et al. 2001</td>
<td>II</td>
<td>29</td>
<td>Bone graft harvested from the iliac crest or other appropriate site vs. calcium phosphate</td>
<td>6 months</td>
<td>Overall Success</td>
<td>9</td>
<td>8</td>
<td></td>
<td>$p=0.29^*$</td>
</tr>
<tr>
<td>Bucholz, et al. 1988</td>
<td></td>
<td>40</td>
<td>Autogenous bone graft vs. porous hydroxyapatite</td>
<td>15.4-34.5 months</td>
<td>Knee pain</td>
<td>3</td>
<td>2</td>
<td></td>
<td>$p=0.63^*$</td>
</tr>
</tbody>
</table>

* = AAOS Calculated arcsine transform
KEY QUESTION 4
Do patients with contained defects from tumor (or other benign bone cysts) have different clinical outcomes when treated with synthetic bone void filler, autograft, or allograft?

Our literature searches did not identify any peer reviewed data that addresses this question. This question specifically addresses the comparison of synthetic bone void filler to either autograft or allograft in patients with contained defects from a tumor.
<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>Reason for Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hirata, et al. 2006</td>
<td>Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumors</td>
<td>Does not answer the question: non-comparative data</td>
</tr>
<tr>
<td>Uchida, et al. 1990</td>
<td>The use of calcium hydroxyapatite ceramic in bone tumor surgery</td>
<td>Does not answer the question: non-comparative data</td>
</tr>
<tr>
<td>Biau, et al. 2007</td>
<td>Allograft-prosthesis composites after bone tumor resection at the proximal tibia</td>
<td>Allograft only</td>
</tr>
</tbody>
</table>
KEY QUESTION 5
Do patients with contained defects from peri-prosthetic bone loss have different clinical outcomes when treated with synthetic bone void filler, allograft, or autograft?

Our literature searches did not identify any peer reviewed data that addresses this question.
DISCLAIMER

As noted above, this document is not intended to convey any official AAOS position on synthetic bone void fillers versus autograft or allograft for peri-prosthetic bone loss. We provide this Technology Overview as a service to our members in an effort to help them identify and evaluate the available published literature on this topic. We hope that our summary will assist physicians in providing the best possible care to their patients.

AAOS would like to have feedback from its members on this Technology Overview. To provide your feedback, please visit http://research.aaos.org/surveys/Tech-Feedback.htm
IV. APPENDIXES

APPENDIX I
INCLUSION CRITERIA

We used the following criteria to determine whether studies should be included in this systematic review:

- Study must be of humans, no *in vitro* or biomechanical studies will be included.
- Studies must be of adults (>18 years old) (80% or more of study population must be >18 years old)
- Study must have enrolled 10 or more patients in any arm
- Study must have been published in 1980 or later
- Study must be published in English
- Study must quantitatively express its results (e.g., studies that express results as “most patients improved” are excluded)
- The quality of studies with loss to follow up of <80% will be downgraded. Less than 50% follow-up will cause the study to be excluded.
- Retrospective case series and manufacturer marketing information are excluded.
- Studies must be prospective cohorts and have concurrent comparison groups (contemporary controls for RCTs and cohort comparisons; case control studies must have concurrent controls). Retrospective comparative studies will be included.
- Study must be a full report, published in a peer-reviewed journal. Meeting abstracts, traditional reviews, and text chapters will not be included.
- Product names are not mentioned in the technology overview.
- If there are duplicate publications of the same study, the most recent publication will be included unless the earlier publication contains information not in the later one. In this latter case, both publications will be included.
- Only studies of the highest level of available evidence will be included for any given question, assuming that there are two or more studies of that higher level. For example, if there are two Level II studies that address a question, Level III and IV studies will not be included. If there is only one Level II study, Level III studies will be included.
- Data on patient-oriented outcomes will take precedence over data on surrogate outcomes.
- We will not consider biomechanical or *in vitro* studies.
APPENDIX II
DATABASES SEARCHED AND SEARCH STRATEGIES
Total # de-duplicated citations: 1508

PubMed Search Strategies

#1

#2

#3

#4

#5
(#1 AND #2 AND #3) NOT #4

EMBASE
Search strategies

#1
((bone OR bony) AND void AND filler*) OR bioglass OR nanomatrix OR nanomatrices OR ((absorbable OR reabsorbable) AND bone AND cement*) OR 'composite bone graft' OR ((silicate* OR Silicate/de OR 'calcium phosphate'/de OR 'calcium phosphate ceramic'/de OR ((calcium OR
tricalcium) AND phosphate*) OR sulfate OR sulfate/exp OR osteoconductive OR hydroxylapatite* OR hydroxyapatite* OR hydroxyapatite/de OR (ceramic* AND collagen) OR 'hyaluronic acid' OR 'hyaluronic acid'/de OR 'polylactic acid'/de OR PLA OR conductive) AND (filler* OR substitute* OR substrate* OR scaffold* OR matrix OR matrices OR replacement* OR void OR voids OR 'bone prosthesis'/de)))

#2 ('spine fusion'/exp OR ((spine OR spinal) AND (fused OR fusion OR arthrodesis)) OR fracture/de OR fracture* OR peri-prosthetic OR osteolysis OR osteolysis/de OR acroosteolysis/de OR ((tumor* OR lesion* OR cyst OR cysts) AND (bone OR bony OR bone/exp)) OR 'bone tumor'/exp OR 'bone cyst'/exp OR chondroblastoma OR chondroblastoma/de OR enchondroma OR 'eosinophilic granuloma'/de OR 'eosinophilic granuloma' OR 'chondromyxoid fibroma')

#3 [article]/lim AND [English]/lim AND [1980-2009]/py AND [embase]/lim

#4 ([animals]/lim NOT [humans]/lim) OR cadaver/de OR biomechanic*:ti OR 'case report':ti OR 'abstract report'/de OR book/de OR editorial/de OR letter/de OR 'retrospective case series' OR rat:ti OR rats:ti OR rabbit:ti OR rabbits:ti)

CINAHL Search strategies

S1 ((bone or bony) and void and filler*) or bioglass or nanomatrix or nanomatrices or ((absorbable or reabsorbable) and bone and cement*) or (composite and bone and graft) or (silicates or MH Silicates+ or hydroxylapatite* OR hydroxyapatite* or MH Hydroxyapatites+ or MH "Calcium Phosphate+" or ((calcium or tricalcium) and phosphate*) or sulfate or MH Sulphates+ or osteoconductive or (ceramic* and collagen) or "hyaluronic acid" or MH "Hyaluronic Acid" or "polylactic acid" or PLA or conductive) and (filler* or substitute* or substrate* or scaffold* or matrix or matrices or replacement* or void or voids or MH "Bone Substitutes+")

S2 MH "spinal fusion+" or ((spine or spinal) and (fused or fusion or arthrodesis)) or MH "Fractures,Bone+" or MH osteolysis+ or ((tumor or tumors or lesion* or cyst) and (bone or bony or MH "bone and bones+")) or MH "bone neoplasms+" or MH "bone cysts" or chondroblastoma or MH "chondromyxoid fibroma" or enchondroma or (eosinophilic and granuloma) or (chondromyxoid and fibroma)

S3 PT "editorial" or PT "letter" or PT "case study" or TI "case report" or MH "in vitro" or TI "in vitro" or TI biomechanic* OR MH cadaver or "retrospective case series" or TI rat or TI rats or TI rabbit or TI rabbits or MH animals+ or MH mammals+

S4 (S1 and S2 and LA English and PY 1980-2009) not S3
Cochrane Library Search strategy

((bone or bony) and void and filler*) or bioglass or ((silicates or hydroxyapatite* or ((calcium or tricalcium) and phosphate*) or sulfate or osteoconductive or ceramic* or "hyaluronic acid" or "poly lactic acid") and (filler* or substitute* or substrate* or scaffold* or matrix or matrices))

APPENDIX III
STUDY ATTRITION

Literature search yielded 1508 citations

Abstract review excluded 1414 citations
Manual bibliography searches identified 16 articles

94 articles underwent full text review
(78 from literature search, 16 from bibliography search)

73 articles excluded after full text review

21 comparative studies underwent data extraction

16 studies were excluded after quality appraisal

5 comparative studies were included
APPENDIX IV
We assessed the quality of each available study was using a two step process. First, we assigned a Level of Evidence to each study included in this *Overview* on the basis of its design. For example, randomized controlled trials were categorized as Level I evidence, non-randomized controlled trials and other prospective comparative studies were categorized as Level II studies, retrospective comparative studies and case-control studies were initially categorized as Level III studies, and case-series studies/reports were categorized as Level IV studies. However, the quality of a study is not necessarily captured by looking only at its design. Therefore, we also used a study quality checklist (see below) and, when quality standards were not met, downgraded the Level of Evidence by one. As such, our use of Levels of Evidence ties these Levels to study quality.

When there were two or more studies of higher quality evidence that addressed a given question, we included only those higher level studies. For example, if there were two Level II articles that address a question, we did not include Level III or lower Level studies.

**STUDY QUALITY CHECKLISTS**

When determining the quality of the evidence, we begin by considering study design. Better study designs are given higher ratings (i.e. randomized control trials are initially evaluated as Level I studies and non-comparative case series are initially evaluated as Level IV studies). The quality checklist is then used to determine if there are flaws that could influence the outcomes in a study. The checklist is completed for each outcome the study reports. It is also completed for each time point that a study reports. For example, if a study reports two outcomes at three different times, the checklist is completed six times.

Items are answered “Yes”, “No”, or “Not Reported”. “Not applicable” is not an acceptable answer for any of the items except when evaluating a crossover trial and the question is about such a trial.

To score the checklist for a study that is a randomized controlled trial, prospective, non-randomized controlled study, retrospective comparative (i.e., controlled) study, or a case series, each “No” answer is scored as –1, and each “Not Reported” as –0.5. If 1 or more points is deducted, the study is downgraded by one Level for that outcome. Studies can only be downgraded by one level. We never downgrade two (or more) levels. Preference is always given to patient-oriented outcomes. If data for surrogate outcomes is examined, the data should be downgraded one level for the surrogate outcome.

To score the checklist for prognostic studies, prospective multiple regression studies start at Level I and retrospective multiple regression studies start at Level II. They are scored as indicated above using the checklist for prognostic studies.

For joint registries, if the reviewer answers “no” to any question or “unclear” to two or more questions, the registry is downgraded one level.

**RANDOMIZED CONTROLLED TRIALS**

1. Did the study employ stochastic randomization?
2. Was there concealment of allocation?
3. Were subjects blinded to the treatment they received?
4. Were those who assessed/rated the patient’s outcomes blinded to the group to which the patients were assigned?
5. Was there more than 80% follow-up for all patients in the control group and the experimental group on the outcome of interest?
6. Did patients in the different study groups have similar levels of performance on ALL of the outcome variables at the time they were assigned to groups?
7. For randomized crossover studies, was there evidence that the results obtained in the study’s two experimental groups (in period 1 and 2) did not differ?
8. For randomized crossover studies, was there evidence that the results of the two control groups (in period 1 and 2) did not differ?

**PROSPECTIVE NON-RANDOMIZED CONTROLLED STUDIES**
1. Were the characteristics of patients in the different study groups comparable at the beginning of the study?
2. Did patients in the different study groups have similar levels of performance on ALL of the outcome variables at baseline?
3. Were all of the study’s groups concurrently treated?
4. Was there more than 80% follow-up for all patients in the control group and the experimental group on the outcome of interest?
5. Did the study avoid collecting control group data from one center and experimental group data from another?
6. For crossover studies, was there evidence that the results obtained in the study’s two experimental groups (in period 1 and 2) did not differ?
7. For crossover studies, was there evidence that the results of the two control groups (in period 1 and 2) did not differ?

**RETROSPECTIVE COMPARATIVE (I.E., CONTROLLED) STUDIES**
1. Was there less than 20% difference in completion rates in the study’s groups?
2. Were all of the study’s groups concurrently treated?
3. Was the same treatment given to all patients enrolled in the experimental and
4. Were the same laboratory tests, clinical findings, psychological instruments, etc. used to measure the outcomes in all of the study’s groups?
5. Were the follow-up times in all of the study’s relevant groups approximately equal?
6. Was there more than 80% follow-up for all patients in the control group and the experimental group on the outcome of interest?
7. Did the study avoid collecting control group data from one center and experimental group data from another?
8. Did patients in the different study groups have similar levels of performance on ALL of the outcome variables at the time they were assigned to groups?
9. Were the characteristics of patients in the different study groups comparable at the beginning of the study?

**CASE SERIES**
1. Was enrollment in the study consecutive?
2. Was there more than 80% follow-up for all patients on the outcome of interest?
3. Were the same laboratory tests, clinical findings, psychological instruments, etc. used to measure the outcomes in all patients?
4. Were the patients instructed/not given concomitant or adjuvant treatments?
5. Were the follow-up times for all patients approximately equal?
APPENDIX V
DOCUMENTATION OF APPROVAL

AAOS Task Force Draft Completed January 8, 2010
Manufacturer Review Completed February 4, 2010
AAOS Guidelines and Technology Oversight Committee February 23, 2010
AAOS Evidence Based Practice Committee February 23, 2010
AAOS Council on Research Quality Assessment and Technology March 3, 2010
AAOS Board of Directors March 8, 2010

AAOS BODIES THAT APPROVED THIS TECHNOLOGY OVERVIEW

Guidelines and Technology Oversight Committee
The AAOS Guidelines and Technology Oversight Committee (GTOC) consists of sixteen AAOS members. The overall purpose of this Committee is to oversee the development of the clinical practice guidelines, performance measures, health technology assessments, and utilization guidelines.

Evidence Based Practice Committee
The AAOS Evidence Based Practice Committee (EBPC) consists of ten AAOS members. This Committee provides review, planning, and oversight for all activities related to quality improvement in orthopaedic practice, including, but not limited to evidence-based guidelines, performance measures, and outcomes.

Council on Research, Quality Assessment, and Technology
To enhance the mission of the AAOS, the Council on Research, Quality Assessment, and Technology promotes the most ethically and scientifically sound basic, clinical, and translational research possible to ensure the future care for patients with musculoskeletal disorders. The Council also serves as the primary resource to educate its members, the public, and public policy makers regarding evidenced-based medical practice, orthopaedic devices and biologics regulatory pathways and standards development, patient safety, occupational health, technology assessment, and other related areas of importance.

The Council is comprised of the chairs of the AAOS Biological Implants, Biomedical Engineering, Evidence Based Practice, Guidelines and Technology Oversight, Occupational Health and Workers’ Compensation, Patient Safety, Research Development, and US Bone and Joint Decade committees. Also on the Council are the AAOS second vice-president, representatives of the Diversity Advisory Board, the Women's Health Issues Advisory Board, the Board of Specialty Societies (BOS), the Board of Councilors (BOC), the Communications Cabinet, the Orthopaedic Research Society (ORS), the Orthopedic Research and Education Foundation (OREF), and three members at large.

Board of Directors
The 17 member AAOS Board of Directors manages the affairs of the AAOS, sets policy, and determines and continually reassesses the Strategic Plan.
APPENDIX VI

TASK FORCE

John S Kirkpatrick MD, Chair
University of Florida
655 W Eighth Street C-126
Jacksonville FL. 32209

Charles N Cornell MD
Hospital for Special Surgery
535 E 70th Street STE 642
New York, NY 10021

Bang H. Hoang MD
Department of Orthopeadic Surgery
University of California Irvine
101 The City Drive South Pavillion III
Orange, CA 92868

Wellington Hsu MD
Northwestern University Feinburg School of Medicine
676 N St. Clair Ste 1350
Chicago, IL 60611

J. Tracy Watson MD
St. Louis University Hospital
7th FL Desolge Towers
3635 Vista Ave.
Saint Louis MO 63110

Guidelines and Technology Oversight Chair

William C. Watters III, MD
Houston, TX 77030

AAOS Staff

Charles M. Turkelson, PhD
Director of Research and Scientific Affairs
6300 N. River Road
Rosemont, IL 60018

Janet L. Wies, MPH
Manager, Clinical Practice Guidelines

Sara Anderson, MPH
Lead Research Analyst

AAOS Medical Librarian
Kristin Hitchcock, MLS
Medical Librarian
CONFLICT OF INTEREST

All members of the AAOS task force disclosed any conflicts of interest prior to the development of the key questions for this technology overview. Conflicts of interest are disclosed in writing with the American Academy of Orthopaedic Surgeons via a private on-line reporting database.

John S Kirkpatrick, MD 1 (Cervical Spine Research Society; Southern Orthopaedic Association); 2 (Journal of surgical Orthopaedic Advances (formerly Journal of Southern Orthopaedic Association)); 5A (AAOS expert witness; Department of Health and Human Services (FDA)); 8 (Bristol-Myers Squibb; Johnson & Johnson; Pfizer; Zimmer). Submitted on: 09/21/2009. *

Charles N Cornell, MD 1 (Hospital for Special Surgery); 2 (Clinical Orthopaedics and Related Research; Journal of Bone and Joint Surgery - American); 3 (Exactech, Inc); 5B (Exactech, Inc); 7 (Exactech, Inc). Submitted on: 05/18/2009. *

Bang H Hoang, MD (n) Submitted on: 05/19/2009 and last confirmed as accurate on 12/15/2009. *

Wellington Hsu, MD 5A (Stryker); 7 (Medtronic Sofamor Danek; Baxter Northwestern Alliance; Pioneer Surgical). Submitted on: 11/15/2009. *

J Tracy Watson, MD 1 (Orthopaedic Trauma Association; Foundation for orthopaedic Trauma; National Trauma Institute); 2 (Clinical Orthopaedics and Related Research; Journal of Bone and Joint Surgery - American; orthopaedic Knowledge online trauma co-editor; journal of Trauma); 3 (DePuy, A Johnson & Johnson Company; Smith & Nephew); 5B (Smith & Nephew); 7 (Smith & Nephew). Submitted on: 09/14/2009. *

* Disclosure Items Answered: (n) = Respondent answered 'No' to all items indicating no conflicts. 1=Board member/owner/officer/committee appointments; 2= Medical/Orthopaedic Publications; 3= Royalties; 4= Speakers bureau/paid presentations;5A= Paid consultant or employee; 5B= Unpaid consultant; 6= Research or institutional support from a publisher; 7= Research or institutional support from a company or supplier; 8= Stock or Stock Options; 9= Other financial/material support from a publisher; 10= Other financial/material support from a company or supplier.
APPENDIX VII

Reference List


EXCLUDED STUDIES


Glassman SD, Dimar JR, Carreon LY, Campbell MJ, Puno RM, Johnson JR. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression


Thalgott JS, Giuffre JM, Fritts K, Timlin M, Klezl Z. Instrumented posterolateral lumbar fusion using coralline hydroxyapatite with or without demineralized bone matrix, as an adjunct to autologous bone. *Spine J* 2001;1(2):131-137.


